Showing 20 of 52 recruiting trials for “Duchenne muscular dystrophy”
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old
Research on the Relationship Between Scoliosis, Pain, Quality of Life, and Trunk Muscle Compensation Patterns Among Patients with Duchenne Muscular Dystrophy.
RecruitingNCT06773988 ↗
Follow-up of NIV At Home in Patients with Duchenne Muscular Dystrophy
Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy
RecruitingNCT06564974 ↗
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
NS-050/NCNP-03 in Boys With DMD (Meteor50)
RecruitingNCT06574919 ↗
Clinical and Functional Assessment of Patients With Inherited Non-Duchenne Myopathies in Sohag University Hospital
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy
👨⚕️ Jiwen Wang, Shanghai Children's Medical Center, affiliated to Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Jul 2024View details ↗
RecruitingNCT06093100 ↗
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim
👨⚕️ Jaclyn Tamaroff, MD, Vanderbilt University Medical Center📍 1 site📅 Started Jul 2024View details ↗
Estimation of Non-Reimbursable Costs for Patients With Duchenne Muscular Dystrophy in France
👨⚕️ Isabelle Durand-Zaleski, Professor, Assistance Publique - Hôpitaux de Paris📍 1 site📅 Started May 2024View details ↗
Long Term Follow-up for RGX-202
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
RecruitingNCT06124196 ↗
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD
👨⚕️ Jaclyn Tamaroff, MD, Vanderbilt University Medical Center📍 1 site📅 Started Mar 2024View details ↗
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
Psychoeducation Program for Parents of Children with Duchenne Muscular Dystrophy
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →